The study, published in BMC Psychiatry, enrolled 66 patients with systemic lupus erythematosus and 33 healthy volunteers, all recruited from Taizhou People’s Hospital. Participants underwent neuropsychological assessment and resting-state functional magnetic resonance imaging, a technique that records brain activity while subjects lie still and think of nothing in particular. Rather than treating this spontaneous activity as a static signal, the team focused on a measure called dynamic regional homogeneity, or dReHo. Regional homogeneity reflects how synchronized the activity of neighboring voxels is at any given moment; high homogeneity suggests that a local patch of cortex is firing in a coordinated fashion, while low homogeneity suggests disarray. By computing this metric across sliding time windows, the researchers could track how that local coordination fluctuates over the course of a scan, capturing a dimension of brain function that conventional static analyses miss entirely.

The results were striking. Seven brain regions showed abnormal dynamic regional homogeneity in the lupus patients compared with healthy controls: the left gyrus rectus, the left and right middle temporal gyri, the left and right middle occipital gyri, the left precuneus, and the right calcarine fissure. What unites most of these regions is their role in vision. The calcarine fissure is the cortical landing strip for signals arriving from the eyes, the primary visual processing hub of the brain, while the middle occipital and middle temporal gyri form successive stages of the visual hierarchy, extracting motion, form, and spatial relationships from the raw retinal input. The precuneus, tucked into the medial parietal lobe, weaves visual and memory signals into self-referential thought and social cognition, and the gyrus rectus on the underside of the frontal lobe contributes to emotional and social processing. Functional annotation of the affected regions confirmed this impression, linking the abnormality map primarily to social cognition and visual processing.

Identifying where the brain behaves abnormally is only half the story. The deeper question is why those particular regions, and not others, are vulnerable in lupus. To address this, the team turned to an increasingly popular strategy known as imaging transcriptomics. The Allen Human Brain Atlas provides gene expression data from postmortem tissue sampled across the entire cerebral cortex, and researchers can ask whether the spatial fingerprint of an imaging abnormality, region by region, tracks the spatial fingerprint of any particular set of genes. If brain areas with high expression of a certain gene family are precisely the areas showing the greatest functional disruption, that gene family becomes a plausible molecular suspect. It is an inferential approach, and the authors are careful to describe their findings as hypothesis-generating, but it offers something that pure imaging studies cannot: a bridge from circuits to molecules.

The transcriptomic analysis pointed in a coherent direction. Genes whose cortical expression patterns matched the dReHo alteration map were significantly enriched for functions related to chemical synaptic transmission, the fundamental mechanism by which neurons communicate across the tiny gaps between them. The map also aligned with markers of excitatory neurons, the workhorse cells that drive cortical activity, and with genes preferentially expressed in the visual cortex. Two specific excitatory neuron subclasses stood out: Ex3-Granule-L4 cells, which populate the middle layer of the cortex where sensory input first arrives, and Ex8-Corticothalamic-Projecting-L6 cells, which send feedback from deep cortical layers back down to the thalamus, the brain’s relay station. In other words, the regions most affected in lupus are those built around a dense machinery of excitatory synaptic transmission in the sensory processing stream, suggesting that the disease may be disrupting the very synapses that carry visual and social information through the cortex.

The team went further, correlating the dReHo abnormality map with molecular maps of neurotransmitter systems, each derived from independent imaging and pharmacological data. Eight systems showed meaningful spatial correspondence: the dopamine transporter DAT, the serotonin receptors 5-HT2A and 5-HT6, the inhibitory transmitter GABA, the kappa-opioid receptor, the muscarinic acetylcholine receptor M1, the synaptic vesicle glycoprotein SV2A, and histone deacetylase, or HDAC. Each of these carries its own implications. Serotonin and dopamine are the classic targets of psychiatric pharmacology, and their involvement hints at why lupus patients experience depression, anxiety, and psychosis. GABA is the brain’s principal brake, and a relative loss of inhibitory control could explain the local desynchronization captured by the dReHo metric. SV2A marks the density of synaptic terminals themselves, while HDAC sits at the interface between gene regulation and inflammation, a pathway of particular interest in autoimmune disease.

For clinicians, the study offers a potential explanation for a frustrating clinical reality. Many neuropsychiatric lupus symptoms, from subtle cognitive slowing to visual disturbances and difficulty reading social cues, have historically been attributed to vascular injury, antibody-mediated inflammation, or the psychological burden of chronic illness, yet objective biomarkers have remained scarce. The finding that dynamic local coordination is disrupted specifically in visual and social cognition networks suggests that some of these symptoms may have a measurable functional signature, one that could in principle be detected with a standard resting-state MRI scanner already installed in most hospitals. The involvement of the visual cortex is especially provocative, because visual complaints in lupus are often dismissed as peripheral, confined to the eye itself, when the new data suggest that the brain’s central visual machinery may be quietly reorganizing.

The authors are appropriately measured about what their results can and cannot claim. The sample, while respectable for a study of this kind, comprised 66 patients and 33 controls from a single center, and the imaging-transcriptomic method is correlational by design: it identifies spatial associations between gene expression and functional disruption but cannot prove that any particular gene or neurotransmitter causes the abnormalities. The dReHo alterations could reflect downstream consequences of inflammation, vascular compromise, medication effects, or the immune assault itself, and disentangling these mechanisms will require longitudinal studies that follow patients from disease onset through treatment. Still, the framework is powerful. By anchoring a functional imaging phenotype to synaptic transmission genes, specific excitatory neuron classes, and eight distinct neurotransmitter systems, the study generates a ranked list of molecular targets that pharmacologists and immunologists can now interrogate.

What makes the work emblematic of a broader shift in neuroscience is its methodological synthesis. A decade ago, a rheumatology question would rarely have been answered with a brain atlas of gene expression; today, the tools exist to overlay a patient group’s functional abnormality map onto the transcriptomic landscape of the cortex and read out candidate biology in a single analysis. The Taizhou team’s integration of dynamic fMRI metrics, the Allen Human Brain Atlas, neurotransmitter receptor maps, and single-cell-derived neuron subclass data represents exactly the kind of multi-scale approach that is reshaping how researchers study neuropsychiatric disease. For the estimated millions of people worldwide living with lupus, and particularly for the substantial fraction who experience neurological or psychiatric complications, the study offers something intangible but important: evidence that the fog of neuropsychiatric lupus has structure, that it follows the brain’s molecular geography, and that with the right combination of imaging and genomics, that geography can finally be mapped.

Subject of Research: Dynamic brain activity changes and their transcriptomic correlates in neuropsychiatric systemic lupus erythematosus

Article Title: Dynamic regional homogeneity changes and their genetic correlates in neuropsychiatric systemic lupus erythematosus: a combined transcriptome-neuroimaging study

Article References: Pu, X., Li, Y., Sun, Z., Liu, Y., Ji, W., Yin, X., Wu, Q., Dong, L., Zou, H., Zhang, J., & Xia, J. (2026). Dynamic regional homogeneity changes and their genetic correlates in neuropsychiatric systemic lupus erythematosus: a combined transcriptome-neuroimaging study. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08653-2

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08653-2

Keywords: neuropsychiatric lupus, systemic lupus erythematosus, resting-state fMRI, dynamic regional homogeneity, imaging transcriptomics, Allen Human Brain Atlas, visual cortex, synaptic transmission, neurotransmitters, excitatory neurons, autoimmune disease, brain mapping

The pulvinar is no ordinary relay. While early textbook accounts cast the thalamus as a simple switching station funneling sensory signals to the cortex, the pulvinar sits at the top of the hierarchy as a higher-order hub, coordinating communication between distant cortical networks. It is densely interconnected with visual, attentional, and association cortices, and it has been implicated in attentional filtering, visual salience assignment, and the integration of information across brain-wide networks. Because cortico-cortical pathways in schizophrenia have repeatedly shown disruption in imaging studies, and because the pulvinar orchestrates precisely such long-range coordination, the research team led by Yuanjun Xie and Qiang Hu reasoned that individualized deviations in pulvinar-cortical connectivity might carry a signature of clinical heterogeneity that conventional group-average analyses wash out.

To test that idea, the team assembled resting-state functional MRI data from 746 healthy controls and 387 patients with schizophrenia drawn from multiple scanning sites—a scale that matters, because site-specific differences in scanners and protocols can masquerade as biological signals if not carefully handled. Rather than comparing patients to controls as groups, the researchers built a normative model from the healthy reference data. Normative modeling is a technique borrowed in spirit from growth charts in pediatrics: instead of asking whether a group differs on average, it estimates, for each individual, how far that person’s brain features deviate from the expected range given the healthy population. Each patient thus received an individualized deviation profile describing where and how strongly their pulvinar-cortical functional connections strayed from the norm.

The next challenge was dimensional reduction guided by clinical relevance. Raw connectivity deviation maps contain thousands of features, far too many to cluster meaningfully without the solution being dominated by noise. The team therefore applied a symptom-guided feature selection strategy, retaining the connections whose deviations tracked symptom measures, and then ran unsupervised clustering within this clinically enriched, low-dimensional feature space. Unsupervised clustering is deliberately blind to diagnosis labels; it simply asks whether patients fall into natural subgroups based on their brain deviation patterns. The answer was yes: two partially separable biotypes emerged, and critically, they were not arbitrary mathematical artifacts but carried clinical meaning.

That meaning was anchored most strongly in negative symptom severity. The two biotypes differed significantly on this clinical dimension, and the difference survived statistical adjustment for scanning site and other available covariates—a crucial robustness check in multisite psychiatry research, where demographic and technical confounds can easily manufacture spurious subgroups. In other words, the brain-based split corresponded to a real, measurable difference in how ill patients were in the negative-symptom domain, the domain that most strongly predicts long-term functional outcome and that has proven most resistant to existing antipsychotic medications.

Where in the brain did the symptom-relevant deviations live? The connections that drove the biotype separation showed a structured cortical distribution, concentrated predominantly in the somatomotor, visual, and ventral attention networks. This distribution is intriguing on several counts. The somatomotor network’s involvement resonates with the well-documented motor abnormalities in psychosis, including soft neurological signs and psychomotor slowing that often precede overt illness. The visual network’s prominence fits with the pulvinar’s role as the principal higher-order nucleus of the visual system, and the ventral attention network’s contribution aligns with the salience-processing disturbances long proposed to underlie psychotic experience. Together, the pattern suggests that schizophrenia’s heterogeneity is written, at least in part, into how the pulvinar dialogues with specific cortical systems rather than being a diffuse, nonspecific connectivity decline.

To add molecular context to the circuit-level findings, the team performed imaging-transcriptomic analyses, which link spatial patterns of brain deviation to the spatial expression maps of genes across the cortex. These analyses were explicitly exploratory, but they yielded coherent profiles. Biotype 1 was associated with enrichment of biological processes involving translation, protein targeting, and synaptic organization—pathways pointing toward the machinery that builds and maintains synapses. Biotype 2 showed a distinct profile involving neurodevelopment, synaptic remodeling, and metal-ion homeostasis, hinting at altered developmental and plasticity programs and at the regulation of ions such as zinc and copper that shape synaptic function. The two molecular fingerprints, like the two connectivity patterns, were related but distinguishable, consistent with the notion of partially separable biologies under one diagnostic umbrella.

The researchers also stress-tested their solution. Site-exclusion analyses, in which the clustering was repeated while leaving out individual scanning sites, indicated that the biotype solution was partially stable, although the degree of clinical separation varied from site to site. That variation is an honest caveat: it signals that while the framework captures something real, its sensitivity is not yet uniform across acquisition environments, and multisite harmonization remains a live challenge for connectomic psychiatry.

Perhaps the most clinically provocative—and most cautiously framed—result came from a projection into an independent cohort of patients receiving repetitive transcranial magnetic stimulation, a noninvasive brain stimulation treatment sometimes used for resistant symptoms. When the biotype assignments derived from the pulvinar-cortical deviation framework were applied to this treatment cohort, the researchers observed nominal, uncorrected differences in negative symptom improvement at two weeks between biotypes. However, those differences were not sustained at the four-week follow-up, and the authors are explicit that the finding should be considered hypothesis-generating rather than evidence that the biotypes predict treatment response. Still, the exercise sketches a tantalizing path forward: if brain-defined subgroups could eventually be shown to respond differently to specific interventions, biotyping could move from descriptive science toward personalized treatment selection.

The study’s authors are careful about what their work does and does not establish. The findings support a symptom-guided, pulvinar-centered framework for characterizing schizophrenia’s heterogeneity, but independent replication using prespecified models is required before the biotypes can be considered clinically or biologically valid. That caution is warranted in a field where data-driven subtyping has a history of solutions that fail to travel across datasets. Yet the combination of a large sample, an individualized normative approach, clinical anchoring, covariate-adjusted robustness, molecular context, and a treatment-cohort projection represents an unusually complete methodological pipeline. If the two pulvinar-cortical biotypes hold up under independent replication, clinicians may one day supplement a symptom-based diagnosis with a circuit-based one—distinguishing, at the level of thalamocortical wiring, the different illnesses that today share a single name.

Subject of Research: Pulvinar-cortical functional connectivity deviations defining symptom-relevant schizophrenia biotypes

Article Title: Pulvinar-cortical connectomic deviations identify symptom-relevant biotypes in schizophrenia

Article References: Xie, Y., Liu, W., Guan, M., Yang, R., Wu, D., Ma, H., Wang, Z., & Hu, Q. (2026). Pulvinar-cortical connectomic deviations identify symptom-relevant biotypes in schizophrenia. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04495-4

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04495-4

Keywords: schizophrenia, pulvinar, thalamus, connectomics, normative modeling, resting-state fMRI, negative symptoms, biotypes, imaging transcriptomics, transcranial magnetic stimulation, brain networks, psychiatry

The study began with a straightforward but demanding measurement task. The researchers acquired high-resolution T1-weighted magnetic resonance imaging scans from 73 patients with sporadic ALS and 70 healthy controls, then used the Desikan-Killiany-Tourville atlas to parcellate the cortex into defined regions of interest. For each region they quantified two separate structural phenotypes: cortical surface area, which reflects the sheet-like expansion of the cortex during development, and cortical thickness, which is more closely tied to the density and health of neurons within the cortical column. This distinction matters because surface area and thickness are governed by partly independent genetic programs, and treating them as a single lumped measure can obscure the biology underneath.

The comparisons revealed precise, statistically robust alterations. Patients showed significantly reduced surface area in the left precentral gyrus, the strip of cortex that houses the primary motor neurons whose degeneration drives the muscle wasting and weakness characteristic of ALS. They also showed decreased cortical thickness in the left frontal pole, a region implicated in the cognitive and behavioral changes that frequently accompany the disease, including the frontotemporal dementia spectrum that overlaps clinically with a subset of ALS cases. Both findings survived correction for multiple comparisons across the full cortical parcellation, with false discovery rate adjusted p-values of 0.025, suggesting that the structural signature is not a statistical artifact of scanning dozens of regions simultaneously.

With the anatomical targets established, the team asked a harder question: does the shape of the cortex influence ALS risk, or does the disease reshape the cortex? To address the direction of the relationship, they turned to two-sample Mendelian randomization, a technique that uses genetic variants as naturally randomized instruments to probe causality. The analysis identified nominal associations between ALS risk and several cortical structural phenotypes, including surface area of the paracentral lobule and thickness of the frontal pole. While nominal rather than definitive, these associations are consistent with a model in which cortical architecture and disease susceptibility are intertwined, with certain structural configurations marking regions that are intrinsically more vulnerable to the ALS process.

The next step was the study’s methodological centerpiece: coupling the imaging signatures to gene expression. The researchers drew on the Allen Human Brain Atlas, a postmortem resource that maps the expression of thousands of genes across hundreds of cortical sampling sites, and used partial least squares regression to identify transcriptional programs whose spatial distribution across the cortex mirrors the pattern of surface area and thickness alteration in ALS. They complemented this with a region-wise differential expression analysis to derive intersect gene sets. The result was a catalogue of 215 genes tied to surface area alterations and 979 genes tied to thickness alterations, each representing a molecular fingerprint of the regions that falter in ALS.

Functional enrichment analyses gave these gene sets biological texture. Both sets were enriched in synaptic processes and neuroactive ligand-receptor interaction pathways, pointing to the well-established role of excitatory synaptic dysfunction and glutamatergic signaling in motor neuron degeneration. But the cell-type analysis, performed using expression-weighted cell-type enrichment, produced the study’s most intriguing division. Genes associated with surface area alterations were preferentially expressed in oligodendrocyte-related cell types, the myelin-forming glia that wrap axons and support the metabolic demands of long-range projection neurons. Genes associated with thickness alterations, by contrast, showed astrocyte-related enrichment, implicating the star-shaped support cells that regulate neurotransmitter clearance, blood-brain barrier integrity and metabolic coupling at synapses.

To move from spatial correlation to molecular prioritization, the team deployed summary-data-based Mendelian randomization, or SMR, which integrates genome-wide association study data for ALS with quantitative trait loci that link genetic variants to gene expression and DNA methylation. This approach tests whether the genetic signal associated with a structural phenotype is mediated by altered expression of a nearby gene, effectively triangulating among imaging, genetics and transcriptomics. The analysis nominated two candidate genes: MOBP, associated with the surface area alteration pattern, and ZNHIT3, associated with the thickness pattern. MOBP encodes a myelin-associated protein expressed almost exclusively in oligodendrocytes, fitting neatly with the oligodendrocyte enrichment of the surface area gene set. ZNHIT3, a component of chromatin-remodeling machinery with roles in RNA polymerase transcription, fits less obviously but intriguingly into the astrocyte story.

Independent evidence came from public single-cell RNA sequencing datasets derived from ALS cases carrying the C9orf72 repeat expansion, the most common genetic cause of the disease. In those data, MOBP expression differed significantly in oligodendrocytes, and ZNHIT3 expression was significantly lower in astrocytes, both with p-values below 0.001. The convergence is notable: two genes prioritized through a purely statistical pipeline built on sporadic ALS imaging showed cell-type-specific expression changes in an independent, genetically distinct form of the disease. That cross-validation across modalities and patient populations strengthens the argument that oligodendrocyte dysfunction and astrocyte dysfunction contribute in parallel, and through partly separable molecular routes, to the regional cortical vulnerability observed on MRI.

The findings arrive amid a broader shift in neuroscience toward multimodal data integration. Individual technologies, whether MRI, bulk transcriptomics or single-cell sequencing, each capture only a slice of a disease process that unfolds across scales from molecules to circuits to behavior. By anchoring the analysis to a measurable clinical phenotype, namely region-specific cortical atrophy, and then triangulating across four independent data layers, the study demonstrates a template that could be applied to other neurodegenerative conditions, including Alzheimer’s disease, frontotemporal dementia and Parkinson’s disease, where regional vulnerability is equally striking and equally unexplained. The same framework could also help reconcile why some ALS patients present with pure motor syndromes while others develop early cognitive impairment, potentially reflecting distinct molecular cascades in motor versus frontal cortex.

The authors are careful to frame the work as hypothesis-generating rather than definitive. The imaging cohort was modest in size, the Mendelian randomization associations were nominal, the transcriptomic coupling rests on postmortem atlas data from donors without ALS, and the single-cell evidence comes from a different ALS genotype. Future longitudinal studies tracking cortical structure in at-risk individuals, and experimental models testing whether MOBP and ZNHIT3 perturbation genuinely alters neuronal survival, will be needed to validate biological relevance. Still, by converting an anatomical observation into a shortlist of testable molecular suspects rooted in specific glial cell types, the study offers ALS researchers something the field has lacked: a concrete, data-driven entry point into the question of why the cortex fails where it does, and a roadmap for how imaging genetics can accelerate the search for therapeutic targets in one of medicine’s most relentless diseases.

Subject of Research: Molecular mechanisms of region-specific cortical vulnerability in amyotrophic lateral sclerosis

Article Title: Integrating neuroimaging, transcriptomics and single-cell sequencing identifies candidate molecular features of cortical vulnerability in amyotrophic lateral sclerosis

Article References: Luan, J., Shan, D., Yun, Y., Wang, Y., Ma, M., Wang, H., Ji, X., Jiao, Y., Tang, Y., Li, J., Zhan, Z., Sun, X., Gao, N., Yan, C., Liu, F., Liu, S., & Yu, D. (2026). Integrating neuroimaging, transcriptomics and single-cell sequencing identifies candidate molecular features of cortical vulnerability in amyotrophic lateral sclerosis. BMC Medicine. https://doi.org/10.1186/s12916-026-05247-3

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05247-3

Keywords: amyotrophic lateral sclerosis, cortical thickness, cortical surface area, imaging transcriptomics, Mendelian randomization, SMR, single-cell RNA sequencing, oligodendrocytes, astrocytes, MOBP, ZNHIT3, motor cortex

The research, led by Lubin Gou and Junqiang Lei of the First Hospital of Lanzhou University and Lanzhou University’s First Clinical Medical College, focused on patients with liver cirrhosis without overt hepatic encephalopathy, a stage abbreviated LC-nOHE. This is the window in which the disease has already compromised liver function but has not yet produced the confusion, disorientation, and personality changes that define overt hepatic encephalopathy. Understanding what happens in the brain during this silent phase is critical, because it may reveal the earliest opportunities for intervention before irreversible damage takes hold.

The team recruited 86 patients with liver cirrhosis but no overt encephalopathy, along with 62 healthy controls, and acquired high-resolution three-dimensional T1-weighted magnetic resonance images of every participant’s brain. From these scans, the researchers extracted the volume of the thalamus and three distinct measures of cortical shape: cortical thickness, sulcal depth, and fractal dimension, a measure of the complexity of the brain’s folded surface. Rather than examining these features in isolation, the investigators constructed structural covariance networks, mathematical maps in which brain regions are connected if their anatomical features covary across individuals. Such networks are widely used as proxies for coordinated maturational and degenerative processes, offering a window into how brain regions change together as a system.

The results were striking at multiple levels. Compared with healthy controls, patients with cirrhosis showed enlargement of the thalamus alongside a broad range of cortical morphological abnormalities. At the level of whole-network organization, the thalamo-cortical structural covariance networks of patients displayed reduced segregation, meaning the brain’s specialized modules were less clearly differentiated, and decreased integration, meaning efficient communication across the network was impaired. These two properties, segregation and integration, are hallmarks of a healthy, well-organized brain, and their simultaneous deterioration suggests a fundamental disruption of the architecture that supports cognition.

Zooming in on individual network nodes, the researchers found that the centrality of three regions was significantly reduced in patients: the thalamus itself, the supramarginal gyrus, and the insula. Each of these regions plays a recognizable role in the syndrome. The thalamus relays sensory and motor signals to the cortex and regulates consciousness and alertness; the supramarginal gyrus contributes to language and spatial cognition; and the insula supports interoception and awareness of the body’s internal state. Reduced centrality in these hubs indicates that they had lost influence within the network, becoming less connected to the rest of the brain’s structural architecture.

Perhaps the most clinically significant finding was the relationship between brain changes and liver function. The degree centrality of the thalamus was negatively correlated with liver function measures, meaning that the worse the liver was performing, the more the thalamus had lost its position within the brain’s structural network. This correlation ties the brain imaging directly to the severity of liver disease and supports the idea that the thalamus sits at the front line of the liver-brain axis, the pathway by which hepatic dysfunction, circulating toxins such as ammonia, and systemic inflammation are translated into neural injury.

To move beyond correlation and probe causality, the team applied a technique called causal analysis of structural covariance networks, or CaSCN. This approach examines how changes in one brain region’s morphology relate to changes in others across the progression of disease, allowing researchers to ask which region leads and which follows. The analyses demonstrated that thalamus volume had causal effects on the alterations of cortical morphology as liver dysfunction progressed. In other words, the data are consistent with a model in which the thalamus is not merely another victim of cirrhosis but an active driver, propagating structural changes outward to the cortical regions with which it is connected.

The study then took an unusual additional step: linking the brain imaging to genomics through imaging transcriptomics. Using normative gene-expression profiles from the Allen Human Brain Atlas, the researchers evaluated whether the spatial pattern of causal effects across the cortex overlapped with the spatial distribution of specific genes. It did. The pattern of causal path coefficients was spatially correlated with the expression of particular genes in the normative atlas, suggesting that the cortical regions most vulnerable to thalamus-driven change are also those with distinctive molecular signatures. Gene ontology analyses pointed toward enrichment in biological processes, molecular functions, and cellular components that may help explain why some cortical areas are preferentially affected while others are relatively spared.

Taken together, the findings provide a comprehensive, multilevel view of how the thalamo-cortical circuit becomes progressively vulnerable in liver cirrhosis before overt encephalopathy appears. The enlargement of the thalamus, consistent with processes such as edema or glial changes reported in prior literature on hepatic encephalopathy, appears to initiate a cascade that erodes the segregation and integration of the entire structural network, strips key hubs of their centrality, and reshapes the cortex in patterns governed partly by underlying gene expression. Because the thalamus’s network position tracks liver function, measures of thalamo-cortical network integrity could potentially serve as imaging biomarkers for identifying patients at risk of progressing to overt hepatic encephalopathy, enabling earlier monitoring and treatment.

The authors emphasize that these findings offer a potential mechanism-driven framework for understanding the earliest brain consequences of liver disease, one that connects organ function, network neuroscience, and transcriptomics within a single analytical pipeline. The work was supported by the Lanzhou University First Affiliated Hospital Foundation and the Science and Technology Department of Gansu Province, and it was approved by the Institutional Ethics Committee of the First Hospital of Lanzhou University. As cirrhosis continues to affect millions worldwide, studies like this one bring clinicians closer to detecting, and perhaps preventing, the neurological toll of liver disease before it announces itself in the clinic.

Subject of Research: Structural covariance network alterations of the thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy

Article Title: Multilevel structural covariance network alterations of thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy: associations with liver function and imaging transcriptomics

Article References: Gou, L., Ren, H., Xu, W., Gao, Y., Wang, S., Zhang, Y., Dou, Y., & Lei, J. (2026). Multilevel structural covariance network alterations of thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy: associations with liver function and imaging transcriptomics. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02790-6

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02790-6

Keywords: liver cirrhosis, hepatic encephalopathy, thalamus, thalamo-cortical circuit, structural covariance network, MRI, liver-brain axis, imaging transcriptomics, cortical thickness, liver function, neuroimaging, Allen Human Brain Atlas